Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by AstraZeneca Pharmaceuticals LP
Lobbying Relationship
Bills mentioned
S.1720: Harriet Tubman Currency Tribute Act of 2015
Sponsor: Jeanne Shaheen (D-N.H.)
H.R.9: Innovation Act
Sponsor: Robert W. Goodlatte (R-Va.)
S.214: Shareholder Protection Act of 2015
Sponsor: Robert Menendez (D-N.J.)
S.214: Preserve Access to Affordable Generics Act
Sponsor: Amy Klobuchar (D-Minn.)
S.1720: Patent Transparency and Improvements Act of 2013
Sponsor: Patrick J. Leahy (D-Vt.)
H.R.4679: Stop Corporate Inversions Act of 2014
Sponsor: Sander M. Levin (D-Mich.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| James French | Counsel, House Judiciary Committee |
| Carlyle Thorsen | General Counsel & AA, Rep. Tom DeLay Deputy Asst. Attorney General, Dept. of Justice Counsel, House Judiciary Committee Legislative Counsel, Rep. McCollum & LoBiondo General Counsel & AA, Rep. Tom DeLay; Deputy Asst. Attorney General, Dept. of Justice; Counsel, House Judiciary Committee; Legislative Counsel, Rep. McCollum and LoBiondo |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate